FHR-3 Inhibitors

FHR-3 Inhibitors encompass a range of chemical compounds that indirectly reduce the functionality of factor H-related protein 3 (FHR-3) by targeting various components of the complement system, which is the primary biological process FHR-3 is involved in. Monoclonal antibodies such as Eculizumab and its pegylated form, Eculizumab Pegol, achieve this by binding to complement protein C5, preventing its cleavage and subsequent formation of C5 convertases, thereby reducing the involvement of FHR-3 in this cascade. Similar effects areachieved by OmCI and Coversin, both of which bind to C5 to inhibit its cleavage. The cyclic peptide Compstatin and the pegylated peptide Pegcetacoplan inhibit the cleavage of complement component C3, while Iptacopan and LNP023 target factor B, a critical component for C3 convertase formation, all contributing to the reduced functionality of FHR-3 by limiting the formation of convertases that FHR-3 regulates. CR2-Crry, a fusion protein, also diminishes FHR-3's activity by binding to C3b and inhibiting the alternative pathway of complement activation.

Complement cascade inhibitors such as Nafamostat, which inhibits Factor D, and PMX-53, a C5a receptor antagonist, both contribute to the diminished activity of FHR-3 by attenuating the formation and action of complement components downstream of C3 and C5 convertases. SBI-087, a small molecule inhibitor of Btk kinase, indirectly limits the classical pathway of complement activation, thus reducing the role of FHR-3 in complement regulation. Collectively, these inhibitors strategically impair the complement system at different points, leading to an overall diminution of FHR-3's regulatory functions in this pathway. The precise targeting of the complement cascade components by these inhibitors effectively curtails the functional involvement of FHR-3, establishing a comprehensive inhibitory effect without directly altering its expression or attacking the protein itself.